Abstract
The future clinical application of animal-to-human transplantation (xenotransplantation) is of importance to society as a whole. Favourable preclinical data relevant to cell, tissue and solid organ xenotransplants have been obtained from many animal models utilizing genetic engineering and protocols of pathogen-free husbandry. Findings have reached a tipping point, and xenotransplantation of solid organs is approaching clinical evaluation, the process of which now requires close deliberation. Such discussions include considering when there is sufficient evidence from preclinical animal studies to start first-in-human xenotransplantation trials. The present article is based on evidence and opinions formulated by members of the European Society for Organ Transplantation who are involved in the Transplantation Learning Journey project. The article includes a brief overview of preclinical concepts and biology of solid organ xenotransplantation, discusses the selection of candidates for first-in-human studies and considers requirements for study design and conduct. In addition, the paper emphasizes the need for a regulatory framework for xenotransplantation of solid organs and the essential requirement for input from public and patient stakeholders.
| Original language | English |
|---|---|
| Pages (from-to) | 2006-2018 |
| Number of pages | 13 |
| Journal | Transplant International |
| Volume | 34 |
| Issue number | 11 |
| Early online date | 6 Oct 2021 |
| DOIs | |
| Publication status | Published - Nov 2021 |
Bibliographical note
for ESOT Workstream 1 of the TLJ (Transplantation Learning Journey) ProjecFunding Information:
MIB, GB, MH, GM, LM, JN, MN, RO, RNP and CW report no conflicts of interest. SS received grants/research support from Novartis, Sandoz, Bridge to Life, Chiesi, Neovii and Organ Recovery; speakers’ bureaux/honoraria from Astellas, Novartis, BMS, Sanofi, OrganOx and Chiesi; and consulting fees from Astellas, Novartis, Teva, Sandoz, Merck, Atara and NefroHealth. EC reports a consulting agreement with Hansa BioPharma. EB is a shareholder in ITB‐MED. KF reports consulting agreements with Hansa BioPharma, Talaris, Otsuka, Palladio Biosciences, Travere Therapeutics, Bayer, Gilead, eGenesis and Veloxis. IJ has received speaker fees from XVIVO Perfusion. BR is CEO of xTransplant. LS is a consulting scientist on safety for XenoTherapeutics and has received funding from MVD Diagnostics for research and development of veterinary diagnostics.
Funding Information: This initiative was supported by the European Society for Organ Transplantation.
Publisher Copyright: © 2021 Steunstichting ESOT. Published by John Wiley & Sons Ltd.
© 2021 Steunstichting ESOT. Published by John Wiley & Sons Ltd.
Fingerprint
Dive into the research topics of 'Organ transplants of the future: planning for innovations including xenotransplantation'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver